JP7738296B2 - 薬物毒性評価方法 - Google Patents

薬物毒性評価方法

Info

Publication number
JP7738296B2
JP7738296B2 JP2021552456A JP2021552456A JP7738296B2 JP 7738296 B2 JP7738296 B2 JP 7738296B2 JP 2021552456 A JP2021552456 A JP 2021552456A JP 2021552456 A JP2021552456 A JP 2021552456A JP 7738296 B2 JP7738296 B2 JP 7738296B2
Authority
JP
Japan
Prior art keywords
cells
drug
liver
drugs
organoids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021552456A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021075528A1 (https=
Inventor
貴則 武部
憲和 佐伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Yokohama City University
Original Assignee
Takeda Pharmaceutical Co Ltd
Yokohama City University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd, Yokohama City University filed Critical Takeda Pharmaceutical Co Ltd
Publication of JPWO2021075528A1 publication Critical patent/JPWO2021075528A1/ja
Application granted granted Critical
Publication of JP7738296B2 publication Critical patent/JP7738296B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5055—Cells of the immune system involving macrophages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/12—Hepatocyte growth factor [HGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/237—Oncostatin M [OSM]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1157—Monocytes, macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/14—Coculture with; Conditioned medium produced by hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/28—Vascular endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/04—Screening or testing on artificial tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2021552456A 2019-10-17 2020-10-16 薬物毒性評価方法 Active JP7738296B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019189838 2019-10-17
JP2019189838 2019-10-17
PCT/JP2020/039023 WO2021075528A1 (ja) 2019-10-17 2020-10-16 薬物毒性評価方法

Publications (2)

Publication Number Publication Date
JPWO2021075528A1 JPWO2021075528A1 (https=) 2021-04-22
JP7738296B2 true JP7738296B2 (ja) 2025-09-12

Family

ID=75537427

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021552456A Active JP7738296B2 (ja) 2019-10-17 2020-10-16 薬物毒性評価方法

Country Status (6)

Country Link
US (1) US20240125767A1 (https=)
EP (1) EP4047082A4 (https=)
JP (1) JP7738296B2 (https=)
KR (1) KR20220083699A (https=)
CN (1) CN114585746A (https=)
WO (1) WO2021075528A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240110155A1 (en) * 2020-12-17 2024-04-04 Genome Biologics Ug A dual cardiac-blood model system for disease modelling and drug screening
KR102511631B1 (ko) * 2022-06-15 2023-03-20 오가노이드사이언스 주식회사 Pbmc 유래 세포독성 t 세포의 신규 용도
JPWO2024157891A1 (https=) * 2023-01-24 2024-08-02
WO2025009590A1 (ja) * 2023-07-06 2025-01-09 インテグリカルチャー株式会社 組織由来の細胞の培養方法および組織由来の細胞を含む培養装置
CN117757885A (zh) * 2023-12-26 2024-03-26 首都医科大学 一种基于高内涵的肠道菌群代谢物筛选方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120301892A1 (en) 2011-05-27 2012-11-29 Xenotech Llc In vitro test system to evaluate xenobiotics as immune-modulators of drug transport and metabolism in human hepatocytes
JP2016202032A (ja) 2015-04-17 2016-12-08 国立大学法人東北大学 アレルギー型薬物性肝障害の評価方法
WO2018035138A1 (en) 2016-08-15 2018-02-22 Organovo, Inc. Three dimensional bioprinted tumor models for drug testing
WO2018115533A1 (en) 2016-12-23 2018-06-28 Insphero Ag Screenable liver disease models and methods
WO2018218344A1 (en) 2017-05-29 2018-12-06 Stemcell Technologies Canada Inc. Compositions and methods for obtaining organoids
JP2019516384A (ja) 2016-05-25 2019-06-20 ソーク インスティチュート フォー バイオロジカル スタディーズ オルガノイド作製および疾患モデル化のための組成物および方法
JP2019517808A (ja) 2016-06-15 2019-06-27 ミメタス ビー．ブイ． 細胞培養装置及び方法
WO2019122388A1 (en) 2017-12-21 2019-06-27 Koninklijke Nederlandse Akademie Van Wetenschappen Immune cell organoid co-cultures
JP2019129707A (ja) 2016-05-19 2019-08-08 株式会社サイフューズ ヒト由来細胞を含むヘテロスフェロイド

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5841760A (ja) 1981-09-01 1983-03-11 旭化成株式会社 繊維状ヒレブランダイト及びその製造方法
CN106062181A (zh) 2014-02-27 2016-10-26 公立大学法人横滨市立大学 自发组织用细胞集合体的制作方法
WO2017110724A1 (ja) * 2015-12-24 2017-06-29 公立大学法人横浜市立大学 血液細胞を用いた組織・臓器の作製方法
US20170285002A1 (en) 2016-03-16 2017-10-05 Public University Corporation Yokohama City University Method for reconstituting tumor with microenvironment
JP7191041B2 (ja) * 2017-12-27 2022-12-16 明弘 梅澤 機能的肝前駆細胞もしくは肝細胞または機能的小腸上皮前駆細胞もしくは小腸上皮細胞を調製する方法
WO2020170239A1 (en) * 2019-02-21 2020-08-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of generating organoids for high throughput screening of drugs

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120301892A1 (en) 2011-05-27 2012-11-29 Xenotech Llc In vitro test system to evaluate xenobiotics as immune-modulators of drug transport and metabolism in human hepatocytes
JP2016202032A (ja) 2015-04-17 2016-12-08 国立大学法人東北大学 アレルギー型薬物性肝障害の評価方法
JP2019129707A (ja) 2016-05-19 2019-08-08 株式会社サイフューズ ヒト由来細胞を含むヘテロスフェロイド
JP2019516384A (ja) 2016-05-25 2019-06-20 ソーク インスティチュート フォー バイオロジカル スタディーズ オルガノイド作製および疾患モデル化のための組成物および方法
JP2019517808A (ja) 2016-06-15 2019-06-27 ミメタス ビー．ブイ． 細胞培養装置及び方法
WO2018035138A1 (en) 2016-08-15 2018-02-22 Organovo, Inc. Three dimensional bioprinted tumor models for drug testing
WO2018115533A1 (en) 2016-12-23 2018-06-28 Insphero Ag Screenable liver disease models and methods
WO2018218344A1 (en) 2017-05-29 2018-12-06 Stemcell Technologies Canada Inc. Compositions and methods for obtaining organoids
WO2019122388A1 (en) 2017-12-21 2019-06-27 Koninklijke Nederlandse Akademie Van Wetenschappen Immune cell organoid co-cultures

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
COURAU, Tristan et al.，Cocultures of human colorectal tumor spheroids with immune cells reveal the therapeutic potential of，Journal for ImmunoTherapy of Cancer，2019年03月14日，vol.7, no.1，p.1-14，[online], [retrieved on 2020.11.04] Retrieved from the Internet: <URL:https://doi.org/10.1186/s40425-019-0553-9>
DEVI, K. Sanjana P. et al.，Assessing the immunomodulatory role of heteroglycan in a tumor spheroid and macrophage co-culture mo，Carbohydrate Polymers，2015年03月25日，vol.127，p.1-10

Also Published As

Publication number Publication date
WO2021075528A1 (ja) 2021-04-22
EP4047082A4 (en) 2023-08-16
CN114585746A (zh) 2022-06-03
EP4047082A1 (en) 2022-08-24
KR20220083699A (ko) 2022-06-20
JPWO2021075528A1 (https=) 2021-04-22
US20240125767A1 (en) 2024-04-18

Similar Documents

Publication Publication Date Title
JP7738296B2 (ja) 薬物毒性評価方法
Nguyen et al. Functional assays to assess the therapeutic potential of extracellular vesicles
JP7576647B2 (ja) 肝臓オルガノイド疾患モデルおよびその作製方法
Yao et al. Organoids: development and applications in disease models, drug discovery, precision medicine, and regenerative medicine
Masuda et al. Methodological development of a clonogenic assay to determine endothelial progenitor cell potential
Ray et al. Secreted CXCL12 (SDF-1) forms dimers under physiological conditions
EP1391505B1 (en) Stem cells and method of separating the same
Popova et al. Autocrine production of TGF-β1 promotes myofibroblastic differentiation of neonatal lung mesenchymal stem cells
Lucendo-Villarin et al. Development of a cost-effective automated platform to produce human liver spheroids for basic and applied research
Gehmert et al. Angiogenesis: the role of PDGF-BB on adiopse-tissue derived stem cells (ASCs)
Li et al. Integration of Kupffer cells into human iPSC-derived liver organoids for modeling liver dysfunction in sepsis
Kwon et al. Cross talk with hematopoietic cells regulates the endothelial progenitor cell differentiation of CD34 positive cells
Juguilon et al. In vitro modeling of interorgan crosstalk: multi-organ-on-a-chip for studying cardiovascular-kidney-metabolic syndrome
WO2019006127A1 (en) ORGANOIDS DERIVED FROM A SINGLE RENAL CELL
Bajetto et al. Metformin potentiates immunosuppressant activity and adipogenic differentiation of human umbilical cord-mesenchymal stem cells
Li et al. Glioblastoma CD105+ cells define a SOX2− cancer stem cell-like subpopulation in the pre-invasive niche
Park et al. Three-dimensional organoids as a model to study nonalcoholic fatty liver disease
JP7533896B2 (ja) スクリーニング方法および毒性評価法
Yang et al. The new era of cardiovascular research: Revolutionizing cardiovascular research with 3D models in a dish
Jarrosson et al. An avian embryo patient-derived xenograft model for preclinical studies of human breast cancers
Wang et al. Periodontal treatment modulates gene expression of endothelial progenitor cells in diabetic patients
Hannig et al. Control of leucocyte differentiation from embryonic stem cells upon vasculogenesis and confrontation with tumour tissue
JP2019103391A (ja) 単球系統のみに分化するヒト単球前駆細胞およびその単離方法
Salinas-Jazmín et al. A flow cytometry-based assay for the evaluation of antibody-dependent cell-mediated cytotoxicity (ADCC) in cancer cells
TW202600811A (zh) 生成內皮細胞的方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250523

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250805

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250825

R150 Certificate of patent or registration of utility model

Ref document number: 7738296

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150